Basic information
- CAS
1154028-82-6- Standard SMILES
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1- InChIKey
IJMBOKOTALXLKS-UHFFFAOYSA-N- Molecular formula
- C13H14N8O2
- Average molar mass
- 314.3 g/mol
- Monoisotopic mass
- 314.12397172
Overview
Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).
Names & identifiers
- Preferred name
- Molidustat
- IUPAC
- 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one
- English name
- Molidustat(BAY 85-3934)
- Molecular formula
- C13H14N8O2
- Molecular weight
- 314.3
Names & synonyms
Molidustat1154028-82-6BAY 85-39342-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one9JH486CZ13DTXSID801510892-(6-(Morpholin-4-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-onemolidustatumVarenzin-CA12-(6-(morpholin-4-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-one2-[6-(Morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one
Show more names
CS-1728Somatoprim2-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one2-(6-morpholinopyrimidin-4-yl)-4-(1h-1,2,3-triazol-1-yl)-1,2-dihydro-3h-pyrazol-3-one1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-3H-pyrazol-3-one
RefChem:57794DTXCID0073580Molidustat [INN]Molidustat [USAN]BAY-85-3934Molidustat (BAY 85-3934)3H-Pyrazol-3-one, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-Molidustat(BAY 85-3934)
Properties
Computed structural properties
- XLogP
- -0.2
- Topological polar surface area
- 101 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 8
- Rotatable bonds
- 3
- Heavy atoms
- 23
- Formal charge
- 0
- Complexity
- 481
Experimental & physicochemical properties
Animal Drugs
EMA approved medicines: Veterinary medicine
FDA approved animal drugs -> Active ingredient
Physicochemical properties
- Boiling point
- 589.2 · 589.2±60.0 °C(Predicted)
- Density
- 1.67 · 1.67±0.1 g/cm3(Predicted)
- storage temp.
- -20 °C · Store at -20°C
- solubility
- 2 O; · insoluble in EtOH; insoluble in H2O; ≥5.68 mg/mL in DMF
- form
- solid
- pka
- 5.38 · 5.38±0.37(Predicted)
- color
- White to off-white
- InChI
- InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2
- InChIKey
- IJMBOKOTALXLKS-UHFFFAOYSA-N
- SMILES
- N1C=C(N2C=CN=N2)C(=O)N1C1C=C(N2CCOCC2)N=CN=1
- FDA UNII
- 9 JH486CZ13 · 9JH486CZ13
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Danger
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P264, P270, P280, P301+P317, P318, P319, P330, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard information
Hazard Classes and CategoriesAcute Tox. 4 (100%)
Safety data
- Signal word
- Danger
- Symbol(GHS)
- GHS08,GHS07
- Hazard statements
- H372-H360-H302
- Precautionary statements
- P264-P270-P301+P312-P330-P501-P260-P264-P270-P314-P501
Chemistry & industry
Pharmacology
ATC Code
B - Blood and blood forming organs
QB - Blood and blood forming organs
Applications
DescriptionHypoxia-inducible factor (HIF) is the major transcription factor involved in erythropoietin gene expression. Because oxygen-dependent degradation of the α subunit of HIF suppresses erythropoietin expression, stimulation of erythropoiesis by agents that prevent degradation of HIF has been one strategy for managing anemia. BAY 85-3934 stabilizes HIF from degradation in the proteasome by inhibiting HIF-1α prolyl hydroxylase (IC50 = 0.49 μM). Inhibition of HIF prolyl hydroxylase by BAY 85-3934 has been shown to increase endogenous production of erythropoietin. This compound has been investigated in clinical trial for treatment of patients with anemia associated with chronic kidney disease and/or end-stage renal disease.
UsesMolidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia[1][2].
Upstream & downstream products
Upstream raw materials
Related reactions
7 records
Compound notes
Loading…